420 with CNW — CU Anschutz Researchers Studying Users’ Capacity to Drive Under Influence of Marijuana

Researchers at the CU Anschutz School of Public Health have embarked on a paid study focusing on marijuana users to examine impairment levels. Over the past two years, the research has involved more than 200 participants aged between 25 and 55 years. Depending on the amount of marijuana consumed, each study session can last anywhere from three to five hours.

Dr. Ashley Brooks-Russell, a lead researcher at the school, explained, “This study allows us to observe the changes people experience after consuming cannabis, including alterations in driving behavior, reaction times, memory, blood composition and eye characteristics. Police officers, in particular, often examine eye changes as a sign of impairment during traffic stops.”

Brooks-Russell highlighted that cannabis impairment remains a significant issue, contributing to crashes and traffic stops. Unlike other drugs, detecting marijuana impairment is challenging due to the lack of straightforward tools for law enforcement. “We’re particularly interested in how daily cannabis users differ from occasional users. Many people use cannabis for medical reasons and develop tolerance, showing fewer changes compared to those who use it sporadically,” she added.

Participants are placed in a controlled environment during the study, where they consume high-concentration marijuana products such as edibles, dabs or vape pens. Once the substance takes effect, researchers conduct blood tests, administer various assessments on an iPad and evaluate participants’ driving abilities using a simulator. The driving simulator is not designed to measure one’s driving skill but rather to observe any negative changes in driving ability due to cannabis use.

The researchers have observed subtle driving impairments among occasional recreational marijuana users, such as weaving in traffic, delayed reaction times, memory lapses and eye changes.

“Our focus is currently on cannabis alone, but there’s potential to expand the study to include cannabis in combination with other substances. In real-world scenarios, people often use multiple substances that affect different brain parts, leading to varied effects. Understanding these interactions is crucial,” noted Dr. Brooks-Russell.

Additionally, the study aims to involve adults 65 years of age and older, because this demographic is experiencing the fastest growth in cannabis use. “In this age group, there are added complexities, like other medications they may be taking and normal cognitive decline associated with aging,” Brooks-Russell explained.

Ultimately, this research aims to develop a tool, similar to an alcohol breathalyzer, which could assist law enforcement in accurately detecting cannabis impairment and enhancing road safety. The entire cannabis industry, including established companies, such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED), is likely to take an interest in this ongoing study and any actionable outcomes that may result upon its conclusion.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Brazilian Supreme Court Ends Criminalization of Cannabis Possession for Personal Use

The Brazilian Supreme Court recently voted to decriminalize cannabis possession for personal use, joining other Latin American nations in this reform and potentially reducing its substantial prison population. The majority of the justices, since the discussions began in 2015, have supported this move.

The justices now need to decide on the maximum amount of cannabis considered for personal use, with the effective date of the ruling expected soon. The justices who favored the decision noted that decriminalization should only apply to personal use amounts, keeping the sale of drugs illegal.

A 2006 bill passed by the U.S. Congress sought to penalize those who carried minor amounts of drugs, including marijuana, with noncustodial sentences such as community service. However, critics argue that it was too ambiguous, lacking a specific amount to distinguish trafficking from personal.

In response to the Supreme Court’s deliberations, Congress is separately working on a proposal to strengthen drug laws, complicating the legal landscape regarding cannabis possession. The Senate approved an amendment in April criminalizing possession of any illegal substances. This proposal passed the lower House’s constitutional committee on June 12, 2024, and needs approval from at least one more committee before a full House vote.

Should lawmakers approve the bill, it would override the Supreme Court’s decision but could still face constitutional challenges.

Senate President Rodrigo Pacheco stated that it is not within the top court’s jurisdiction to decide on the matter. The court’s decision has long been awaited by legal scholars and activists in Brazil, a country with the world’s third-largest prison population. Critics argue that the current laws often result in users being convicted on trafficking charges and incarcerated in overcrowded prisons, where they face pressure to join gangs.

As of the end of 2023, Brazil had about 852,000 people incarcerated, nearly 25% of whom were detained for drug trafficking or possession. The prison system is overcrowded, and Black individuals are disproportionately affected, comprising more than two-thirds of the inmates.

According to a recent study by the Brazilian research company Insper, Black people were marginally more likely than whites to be charged with drug trafficking. More than 3.5 million records from the public security secretariat of Sao Paulo were examined in this investigation between 2010 and 2020.

Leftist politician Chico Alencar celebrated the decision on social media, calling it a major step forward for Brazil’s drug policy and an issue of public health rather than safety and punishment. However, Gustavo Scandelari, an expert on Brazil’s penal code, contended that even if the court establishes a cap on the amount for personal use, the decision might not result in significant changes. He pointed out that although money plays a role in defining whether someone is viewed as a dealer or a user, it is not the only way.

In other Latin American countries, medical cannabis is permitted, though often under strict regulations. Colombia decriminalized possession about 10 years ago, but a measure to regulate recreational use failed to pass in the Senate last August. Similarly, Peru, Venezuela and Ecuador allow medical use but prohibit possession and distribution for other purposes.

For cannabis companies that could have foreign markets in the sights, such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED), these developments in Brazil may be of more than casual interest since they could later open the door to broader cannabis-policy reforms that allow established companies to enter that market.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Two New Books Explore Marijuana’s Medical Powers

For those interested in exploring marijuana’s medical benefits, two recently published books —Josh Leddy’s “Living with Cannabis: A Personal Journey” and Dr. Benjamin Caplan’s “The Doctor-Approved Cannabis Handbook” — provide essential insights. The books offer both professional guidance and firsthand accounts, making them invaluable for anyone curious about cannabis’s therapeutic uses.

The book by Dr. Benjamin Caplan offers a thorough manual on medical marijuana use. Caplan, a board-certified family physician with experience treating more than 250,000 patients, reveals his in-depth understanding of the ways that cannabis can help with a range of ailments, including cancer, sleeplessness, cognitive decline and chronic pain. The book explores the science of cannabis, providing lucid descriptions of its workings, appropriate products and dosages.

Caplan highlights the value of guided cannabis therapy, which gives patients autonomy over their care regimens and enables individualized and efficient treatment. The guidebook, which has been recommended by both patients and industry professionals, is a vital tool for everyone considering using cannabis to enhance their health.

Melissa Etheridge, a cannabis activist and cancer survivor, gave high marks to the book. “As a cannabis supporter and cancer survivor, I am aware of the significant role that marijuana plays. Dr. Caplan’s latest book provides an abundance of knowledge along with a significant amount of empathy and understanding,” she said.

On the other hand, Leddy’s book offers a firsthand account of his experience using marijuana as a pain reliever without surgery. Leddy, an entrepreneur and athlete, tells his tale of using cannabis’ healing properties to overcome serious injuries and mental-health issues. The book provides helpful guidance on pain management without requiring invasive procedures or prescription drugs.

Leddy’s story is both intimate and educational, describing his struggles with severe pain and how marijuana changed his life. He highlights the emotional and physical health advantages of cannabis while offering readers tools and ways to manage their own pain and live better.

Together, these books present a well-rounded view of the medical uses of cannabis. They combine expert medical advice with real-life experiences, making them essential reads for anyone interested in the potential benefits of cannabis for health and wellness. Whether you are exploring cannabis for personal use or professional knowledge, “Living with Cannabis: A Personal Journey” and “The Doctor-Approved Cannabis Handbook” provide a wealth of information to help you understand and navigate the therapeutic use of cannabis effectively.

These publications are likely to increase public awareness about the therapeutic potential of the different medical cannabis products made by the numerous licensed companies such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED), and this could motivate more patients to try these products to ease their symptoms.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Survey Explores Views of Americans on Cannabis Legalization

As the United States moves closer to rescheduling and legalizing cannabis, critical questions emerge about who should benefit from these changes and who is best suited to craft equitable cannabis policies. Big businesses frequently have a big say in what laws are passed, and the cannabis industry seems to be no exception. But who, in the opinion of Americans, ought to have more influence over cannabis laws?

A recent survey by the Parabola Center, a nonpartisan think tank made up of experts in drug policy and law who advocate for marijuana legalization with a special emphasis on small enterprises and individuals, provides insight into public opinion. When respondents were asked who they trusted to develop effective marijuana policies, they provided the following responses:

67%: individuals with firsthand experience
56%: cannabis users
55%: social-equity advocates
24%: representatives from pharmaceutical companies
22%: federal government
18%: executives from the tobacco industry
13%: executives from the alcohol industry

It makes sense that people have little faith in executives in the alcohol and tobacco industries, given the harmful effects of their products. Furthermore, as their regular customer base shrinks, a few of these businesses are keen to join the cannabis space.

When asked about their top concerns regarding marijuana policy, respondents said the following:

68%: promoting social equity
68%: ending cannabis-related arrests
65%: ensuring access to marijuana
49%: fostering a sharing society
42%: preserving cannabis culture
27%: keeping cannabis illegal

The war on drugs, including marijuana prohibition, disproportionately harmed certain communities. Many believe that fair policies could help address some of the injustices caused by past enforcement. In fact, according to 61% of respondents, legalization should help individuals who have been negatively impacted by current prohibitions.

President Joseph Biden has also acknowledged the negative impacts caused by outdated cannabis policies. He stated in 2022 while announcing a review of how marijuana is classified, that many lives have been upended because of failed cannabis policy approaches, and it was time to make the mistakes right.

When asked who should benefit from cannabis legalization, respondents identified the following top three groups:

85%: people using marijuana for medicinal purposes
73%: workers in the marijuana industry
63%: recreational users

Conversely, the least-favored groups included alcohol companies, the tobacco industry, large corporations and pharmaceutical companies.

The survey, conducted in September 2023, involved 404 U.S. adults. Although not extensive, it may be one of the first surveys to explore this particular angle of marijuana policy and legalization.

Entities such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) will be pleased to see that the general public sentiment is in favor of ending cannabis prohibition at the federal level and allowing experienced industry professionals to be in charge of policy making and implementation.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Signature Collection Can Begin After North Dakota Cannabis Legalization Ballot Initiative Gains Official Approval

Michael Howe, North Dakota’s secretary of state, recently gave the green light for the circulation of a petition aiming to legalize marijuana. If approved, the measure would allow adults aged 21 and older to grow, process, use and sell cannabis. Additionally, it would establish a regulatory body to oversee marijuana-related entities within the state.

The proposal also includes specific regulations concerning processing and production, as well as restrictions on usage, such as in vehicles and public spaces, and provisions for home cultivation.

To qualify for inclusion on the ballot, supporters of the petition must gather a minimum of 15,582 signatures by April 25 next year. Should they meet this deadline by July 8 this year, the legislation will be put to a vote in November’s general election. However, if the required signatures are collected after this date but before next year’s deadline, the legislation will be deferred to the next statewide election, anticipated to occur in 2026.

An advertisement posted on Indeed reveals that advocates of the proposal are seeking North Dakotans to assist in petition circulation across various cities, including Dickinson, Bismarck, Devils Lake, Grand Forks, Fargo, Jamestown, Williston and Minot.

Spearheading the initiative is Steve Bakken, a former mayor of Bismarck and current Burleigh County commissioner. Bakken underlined the need for more efficient use of resources, particularly in the fight against illegal drugs and substances such as fentanyl. He also emphasized the group’s goal of averting the possible adoption of a badly written initiative.

In previous years, voters in the state have rejected similar measures to legalize cannabis, with 55% opposing the proposal in 2022 and an even larger margin against it in 2018. Despite these setbacks, in 2021, the state’s House passed legislation aimed at legalizing and taxing recreational cannabis. However, these efforts were thwarted by the GOP-led senate.

Voters approved medical cannabis in 2016, leading to the establishment of a state-run program that currently serves about 10,000 patients. Additionally, the state’s Pardon Advisory Board introduced a new procedure to streamline pardons for minor cannabis offenses in 2019, resulting in 100 pardons by Governor Doug Burgum.

Currently, 24 states have legalized recreational cannabis, with Ohio being the most recent to do so through a ballot initiative last year. Additionally, similar initiatives are being carried out in other states. Florida is scheduled to vote on a ballot measure in November, and there are active signature-collection campaigns in states including South Dakota, Nebraska and Arkansas.

The opportunity for voters in North Dakota to end marijuana prohibition will likely be watched by industry companies such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) because the enactment of a law creating a marijuana market would give residents the choice to consume marijuana for recreational purposes much like it is happening in other states around the country.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Partial Legalization of Cannabis in Germany to Take Effect in April

The German parliament has given the green light to partially legalize marijuana for recreational personal use, ushering in some of Europe’s most lenient cannabis regulations. The substance was made legal for recreational use in Malta and Luxembourg in 2023 and 2021, respectively. The Netherlands, on the other hand, which is renowned for having lax marijuana laws, has started toughening up on sales to visitors and nonresidents.

The German approval came following a landmark vote in the Upper House, or Bundesrat, where legislators endorsed the measure. Once the new regulations take effect on April 1, 2024, individuals will be allowed to obtain up to 25 grams of marijuana per day through regulated cultivation associations. Additionally, they can cultivate up to three cannabis plants.

While this move represents a progressive stance, especially in comparison to neighboring countries, the law still prohibits cannabis possession and use for individuals under the age of 18, maintaining a degree of caution.

The journey toward approval wasn’t without its challenges. Internal conflicts arose over the marijuana issue within the alliance, which includes the Greens, the Free Democratic Party and Chancellor Olaf Scholz’s Social Democrats. The initial plan to allow cannabis sales in shops was thwarted by the European Union, leading to the formulation of a secondary law aimed at piloting such sales in specific regions.

Ahead of the vote, Karl Lauterbach, the health minister, urged parliamentarians to support the contentious law, citing a surge in youth marijuana consumption sourced from the illicit market. However, opposition voices, such as Simone Borchardt from the Christian Democratic Union, raised concerns about the potential health risks, particularly for young people. Borchardt criticized the coalition government, accusing officials of prioritizing ideology over the nation’s interests.

Despite having already been passed by the Bundestag last month, the legislation still required Bundesrat approval, which it successfully obtained.

Advocates of the measure, such as the German Marijuana Association, highlighted the dangers associated with black-market marijuana, which can be contaminated with various substances, including heroin or synthetic cannabinoids.

Steffen Geyer, head of Berlin’s Hemp Museum, hailed the bill as a move toward a more reasonable and tolerant marijuana policy. Opponents of the law, however, pointed out that cannabis use among the youth might have negative consequences on the central nervous system and raise the risk of schizophrenia and psychosis.

The new regulation is still polarizing public opinion: a recent YouGov survey found 47% in favor and 42% against. This is a reflection of the ongoing discussion about legalizing cannabis and the necessity for rules that strike a balance between protecting individual liberties and public-health issues.

The legal changes to marijuana laws in Germany could eventually open opportunities for established companies such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) that have set their sights on expanding beyond their primary markets.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Study Finds CBD Could Ease Stress, Irritability Linked to Menstruation

A recent study investigated the potential effects of CBD on symptoms related to menstruation, finding that oral doses of CBD helped alleviate various symptoms such as stress, anxiety and irritability compared to participants’ initial conditions. However, depression levels remained unchanged throughout the study period.

The research study marks the first of its kind to explore the impact of cannabidiol specifically on menstrual-related symptoms (MRS) and general irritability. The findings indicated notable reductions in MRS, stress, irritability and anxiety after three months of CBD use compared to baseline measurements.

According to the authors, the results suggest that CBD could serve as an effective treatment for alleviating MRS. Given the limited options for managing MRS and its associated experiences, further exploration of CBD as a treatment option is deemed necessary.

Current remedies for MRS are limited, often involving lifestyle adjustments, behavioral therapies or over-the-counter (OTC) medications. Further, the authors noted that severe psychological symptoms may require pharmacotherapy or hormonal interventions, but these approaches are only effective for a portion of individuals and may entail side effects.

During the trial, participants were instructed to consume CBD softgels two times a day for five days at the onset of menstrual symptoms, for three months. Participants were divided into two groups, one receiving a 160-milligram dose of CBD twice daily and the other receiving 320 milligrams.

Exclusions from the study included individuals who had used marijuana in the past 30 days, those attempting to conceive, individuals with significant health conditions, minors and individuals outside the range of 18 to 55 years of age. One participant withdrew due to skin irritation after a single CBD dose.

Results showed consistent reductions in MRS, irritability, stress, symptom severity and anxiety across both dosage groups compared to baseline. These changes were observed as early as the first month and continued throughout the study period.

Published in the “Experimental and Clinical Psychopharmacology Journal,” the study disclosed support from marijuana companies such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) and Charlotte’s Web.

Limitations of the study included a relatively homogeneous sample, potentially oversampling individuals with moderate MRS severity. The absence of compensation for participants and reliance on self-reported CBD consumption were also noted, suggesting the need for more rigorous verification methods in future research.

Furthermore, the trial lacked a placebo control, leading the authors to acknowledge the possibility of observed symptom reductions being influenced by placebo effects. Despite these limitations, the study offers initial evidence supporting CBD as a management option for MRS, emphasizing the need for further investigation and optimization of CBD administration.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Research Finds 7 in 10 Americans Live in States with Legal Cannabis

Despite federal prohibition, cannabis has gained legal status across many of the states in the United States, whether for recreational or medical use. According to recent research from the Pew Research Center, a majority of Americans, approximately 74%, now reside in states where cannabis is permissible in some form. Among these, about 54% live in states where recreational use is allowed.

Currently, a significant portion of states — 24, along with the District of Columbia — have given the green light to recreational cannabis. Furthermore, 14 states have legalized cannabis solely for medical applications, while the rest, totaling 12 states, have instituted laws allowing access to cannabis products containing minimal or no psychoactive compounds.

The study’s results, which are consistent with the state-by-state strategy, highlight the growing acceptance of cannabis legalization throughout the nation. This trajectory aligns with recent Gallup polling, which indicates that 70% of U.S. citizens favor legalization.

Examining the distribution of cannabis dispensaries, the analysis noted that a substantial majority, approximately 76%, are situated in states permitting recreational use. Another 23% cater to medical cannabis markets. The 1% serve areas where laws support CBD-only or low-THC products. Interestingly, half of the residents in these states (the 1%) have access to a dispensary.

This trend finds its roots in the Farm Bill 2018, which made hemp containing less than 0.3% THC legal, consequently spurring the development of noneuphoric derivatives such as CBD products. However, it also led to the emergence of substances such as delta-8 THC, which occupy a legal gray area. As they become more and more popular, some states,especially those that haven’t legalized cannabis, have started to regulate or outright ban these goods.

When it comes to states that have legalized cannabis, California leads the pack with an astounding 3,659 dispensaries — one-fourth of all stores in the country. However, Oklahoma leads as the state with the highest density of cannabis outlets per capita — 36 for every 100,000 citizens. All told, 79% of U.S. citizens live in counties with at least one of the approximately 15,000 operating cannabis dispensaries.

A closer look at the socioeconomic ramifications of the findings reveals that densely populated locations in states such as Virginia, Maryland, Colorado and Connecticut typically have median household incomes that are at least $20,000 less than those in areas with fewer dispensaries. On the other hand, New York and New Hampshire present a different picture, with areas hosting numerous dispensaries boasting median incomes around $20,000 higher than their counterparts.

As more Americans get an opportunity to legally access marijuana products from state-licensed companies, pressure for regulatory change at the federal level could mount and result in reforms that allow companies such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) to operate freely across the country.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Maryland Legislators Consider Bills Against Workplace Discrimination for Cannabis Users

Legislative committees in Maryland’s state House of Delegates and Senate convened last week to deliberate on proposed measures aimed at shielding workers from repercussions due to off-duty marijuana use. The bills’ essence lies in shifting the burden of proof onto employers, requiring them to demonstrate on-the-job impairment before taking disciplinary action against an employee.

Introduced as SB 513 by Senator Alonzo Washington and as HB 525 by Delegate Jheanelle Wilkins, both bills share near-identical language. The Finance Committee in the Senate heard testimonies on SB 513 on Thursday, while the House’s Economic Matters Committee followed suit with HB 525 a day later. Although no immediate action was taken, extensive testimony was provided by stakeholders, the public and the bills’ sponsors.

Washington underscored the bill’s aim to safeguard employees’ rights in light of Maryland’s legalization of marijuana. Support for the proposal was often cast as a logical step forward, given the state’s legal framework. Organizations such as firefighter associations lent their support, advocating for the protection of members’ rights to off-duty cannabis use.

However, critics voiced concerns regarding potential implications for public safety, suggesting that identifying and addressing impaired workers might become more challenging. Delegate Jesse Pippy expressed surprise at firefighter endorsement of the bill, prompting Wilkins to emphasize the proposal’s focus on better assessing on-the-job impairment.

Despite assurances from supporters, doubts lingered regarding the reliability of methods for gauging impairment.

Numerous speakers, including civil rights groups, professional groups and state officials, testified in support of the bill. NaShona Kess from the Maryland NAACP highlighted the bill’s significance for marginalized communities disproportionately affected by discriminatory employment practices related to cannabis offenses. Further, Cleveland Horton from the Maryland Commission on Civil Rights echoed support for the bill, emphasizing its importance in promoting fairness and equity in employment practices.

Advocates from the Cannabis Policy Project and NORML also provided testimony, stressing the bill’s role in protecting civil liberties and maintaining workplace safety. They cited studies showing no adverse impact on workplace performance due to off-duty cannabis use.

The bill does not prohibit employers from testing for impairment but aims to prevent unjust consequences for employees who use marijuana legally outside of work hours.

Across the country, as cannabis legalization gains momentum, discussions on marijuana-related employment policies have become increasingly prevalent. In Ohio, for instance, Cleveland mayor Justin M. Bibb announced updates to the city’s drug-testing policies to align with modern practices and remove barriers to hiring related to marijuana use.

These bills are a progressive step that the wider cannabis industry, including companies such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED), is likely to welcome as it allows employees who wish to consume marijuana during their off-duty hours to do so.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW – Prohibitionist States See Nearly Double Search Traffic for Delta-8 THC as Legal States

A recent study on the online search behavior concerning delta-8 THC says that the cannabinoid seems to be substantially more common in states where cannabis is still prohibited, based on information obtained from Google Trends. According to an analysis by CBD Nationwide, delta-8 THC online searches were almost twice as common in states where recreational marijuana is still illegal. This indicates that there has been a notable movement toward other cannabinoids in reaction to marijuana prohibitions.

A contributing factor to the popularity of delta-8 in these states is its extensive availability, both online and in physical stores such as gas stations, smoke shops and convenience stores. The cannabinoid, which is usually derived from hemp or synthesized from different parts of the plant, is legal in the United States.

According to the company, the difference in interest in the substance between states with differing cannabis laws was statistically significant, and the results were unlikely to have been caused by random chance, as evidenced by the very low p-value.

Google searches for the cannabinoid have increased dramatically in recent years, the study noted, with an 850% spike in the year 2021 alone. According to a 2023 AMA study, states that prohibit cannabis use may unintentionally promote the use of delta-8 items, a trend likely aggravated by hemp being federally legalized under the Farm Bill 2018.

The CBD Nationwide study indicated that there is more interest in delta-9 THC in states where cannabis is illegal, albeit to a lesser extent. To validate the results, the analysis used statistical tests such as Tukey’s Honestly Significant Difference (HSD) tests and analysis of variance (ANOVA).

The study, however, did not delve into the specific context of these searches, leaving it unclear if individuals in states where cannabis is illegal were seeking cannabinoid products or simply researching related laws and scientific information. Legislators, activists and business interests all have different opinions about how to regulate newly discovered cannabinoids. Certain states have chosen to prohibit or limit the sale of the substances, while others support updated federal regulations that treat intoxication cannabinoids apart from CBD.

State cannabis authorities have asked Congress to take into account laws that cover a wider range of newly discovered cannabinoids rather than only CBD.

Congress is expected to discuss the issue during the upcoming Farm Bill negotiations, which have been delayed due to a short-term extension of the existing legislation.

The analysis of search traffic shows that ending prohibition and letting cannabis companies such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) to operate within a regulated marketplace facilitates public health because residents will not be pushed to try alternatives sourced from gray- or black-market actors.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com